Previous studies in patients with metastatic GC undergoing second-line therapy with Ramucirumab and PTX, revealed that the increase in serum level of circulating VEGFA, as well as a decrease in circulating levels of Ang2 indicated the effectiveness of therapy (46). The gene discussed is ANGPT2; the disease is gastric cancer.